Therefore, the aim of this study was to assess, for the first time, the contribution of the formation of the Bcl-2 and beclin-1 complex in the context of the glioma cell elimination through programmed cell death induction using the combined action of LY294002 and sorafenib. This evidence concerns the gene BECN1 and central nervous system cancer.